Buprenorphine Formulations: Films, Tablets, Injections & More

When you start buprenorphine treatment for opioid use disorder, you may encounter more than one current formulation, including products used under the tongue and clinician-administered extended-release injections. Availability, indications, and insurance coverage change over time.

The formulation you choose can make a real difference in your daily life. Some people prefer the convenience of a once-monthly injection so they don't have to think about medication every day. Others do best with the familiar routine of a daily sublingual film. And for some, cost and insurance coverage end up being the deciding factor.

In this guide, we'll break down every available buprenorphine formulation, explain how they compare in terms of effectiveness and convenience, and help you understand which option might work best for your situation. Whether you're just starting treatment or considering a switch, you'll find the practical information you need here.

What Is Buprenorphine and Why Does Formulation Matter?

Buprenorphine is a partial opioid agonist medication that's considered the gold standard treatment for opioid use disorder. It works by attaching to the same brain receptors that other opioids target, but it activates them only partially — enough to prevent withdrawal and cravings, but not enough to produce a dangerous high.

The way buprenorphine enters your bloodstream affects how well it works and how convenient it is to use. Most formulations are combined with naloxone (an opioid blocker) to discourage misuse, though mono-products containing only buprenorphine are available for specific situations like pregnancy.

Different formulations have different bioavailability — meaning different percentages of the medication actually make it into your bloodstream. They also vary dramatically in cost, insurance coverage, daily routine impact, and how discreet they are to use. Understanding these differences helps you and your provider choose the right option.

Sublingual Films (Suboxone Film, Generic Buprenorphine/Naloxone Film)

Sublingual films are thin, orange, rectangular strips that dissolve under your tongue. Suboxone is the brand name, but several FDA-approved generics are now available at lower cost.

How they work: Films are absorbed through oral mucous membranes. Follow the prescription and instructions for the specific product rather than a generic administration timeline.

Bioavailability: About 30% of the dose reaches your bloodstream when used correctly. Swallowing the film significantly reduces absorption.

Strengths available: 2mg/0.5mg, 4mg/1mg, 8mg/2mg, and 12mg/3mg (buprenorphine/naloxone)

Pros:

• Commonly available, with coverage varying by plan
• Easy to dose precisely and adjust as needed
• Fast onset — you feel relief within 30–60 minutes
• Small and discreet to carry
• Available in multiple labeled strengths; do not cut unless the prescription and pharmacist explicitly permit it

Cons:

• Daily routine required (though some people prefer this structure)
• Unpleasant taste that lingers for some people
• Requires you to avoid eating, drinking, or talking for 10+ minutes
• Can be difficult for people with dry mouth

Who it's best for: People who want flexibility in dosing, prefer daily medication routines, or need to start treatment quickly. Films are also ideal if you're working closely with your provider to find your optimal dose, since adjustments are easy.

Cost: Price varies by product, quantity, pharmacy, insurance, and assistance eligibility. Our guide to copay assistance programs explains questions to ask.

Sublingual Tablets (Subutex, Generic Buprenorphine/Naloxone Tablets)

Sublingual tablets work the same way as films — you dissolve them under your tongue — but they're round pills instead of strips.

How they work: Sublingual tablets are absorbed through oral mucous membranes. Follow the exact product label and prescription instructions.

Bioavailability: Similar to films at around 30%, though some studies suggest slightly lower absorption for tablets in certain formulations.

Strengths available: 2mg/0.5mg and 8mg/2mg combination tablets; 2mg and 8mg mono-product (buprenorphine only, no naloxone)

Pros:

• Often less expensive than films, especially generics
• Some people find tablets easier to use than films
• Mono-product tablets (Subutex) available for pregnancy
• More compact to store than film packages

Cons:

• Take longer to dissolve than films (up to 10 minutes)
• Chalky taste that some people dislike
• Can crumble or break in packaging
• Less flexible for dose splitting than films

Who it's best for: People who prefer tablets over films, those looking for the lowest-cost option, or pregnant individuals who need mono-product buprenorphine. Read our pregnancy safety guide for more details on treatment during pregnancy.

Typical cost: Generic tablets are among the most affordable options at $50–$100 per month with insurance. Mono-product tablets may cost more.

For a detailed comparison of films versus tablets, check out our post on Suboxone film vs tablet.

Monthly Injection (Sublocade)

Sublocade is a once-monthly injection of extended-release buprenorphine administered by a healthcare provider in an office setting.

How it works: Your provider injects Sublocade into the fatty tissue of your abdomen using a special pre-filled syringe. The medication forms a solid deposit under your skin that slowly releases buprenorphine over the course of a month.

Bioavailability: 100% — since it's injected, all of the medication eventually enters your bloodstream, though it's released gradually.

Strengths available: Consult current FDA labeling and the prescriber; available strengths and initiation requirements are product-specific.

Pros:

• No daily medication routine to remember
• Eliminates risk of diversion or misuse
• Steady medication levels without daily peaks and valleys
• Impossible to "forget" a dose
• After discontinuation, buprenorphine levels taper naturally over several months
• Particularly valuable for people in structured settings or with housing instability

Cons:

• Requires monthly clinic visits for injection
• Product-specific initiation and maintenance requirements determined by the prescriber using current labeling
• Injection site reactions in about 5% of patients
• Expensive without insurance ($1,500–$2,000 per month)
• Limited ability to adjust dose quickly if needed
• Not ideal if you're still finding your optimal dose

Who it may fit: Eligibility depends on current product labeling, clinical stability, prior treatment, and prescriber assessment. Do not transition based on an online dose threshold.

We've written an in-depth guide about Sublocade monthly buprenorphine injection if you want more details.

Typical cost: Most major insurance plans cover Sublocade after prior authorization. Medicaid coverage varies by state. The manufacturer offers patient assistance programs. Without insurance, monthly costs can exceed $1,500.

Request a clinical evaluation to discuss available treatment options. This article does not establish that every formulation is offered.

Weekly and Monthly Injections (Brixadi)

Brixadi is a newer extended-release buprenorphine injection available in both weekly and monthly formulations, approved by the FDA in 2023.

How it works: Similar to Sublocade, Brixadi is injected into abdominal fat by a healthcare provider. It uses a different extended-release technology that allows for both weekly and monthly dosing options.

Bioavailability: 100% — injected medication has complete bioavailability over time.

Strengths available:

• Weekly: 8mg, 16mg, 24mg, 32mg
• Monthly: 64mg, 96mg, 128mg

Pros:

• More dosing flexibility than Sublocade
• Weekly option for people who need closer monitoring initially
• Can transition between weekly and monthly as stability improves
• Smaller injection volume than Sublocade
• Less stringent initiation requirements

Cons:

• Even newer than Sublocade, so less real-world data
• Not as widely available yet
• Similar cost challenges as Sublocade
• Weekly dosing requires more frequent clinic visits
• Insurance coverage still being established

Who it's best for: People who want injectable buprenorphine but need more frequent dosing initially, or those transitioning from daily sublingual who aren't ready for monthly injections. The weekly option can be helpful during early stabilization.

Typical cost: Similar to Sublocade at $1,500+ per month without insurance. Coverage varies widely by plan and is still being established with many payers.

Mono-Product Buprenorphine (Subutex, Generic)

Mono-product formulations contain only buprenorphine without naloxone. They come in sublingual tablets.

How they work: Identical to combination sublingual tablets — dissolve under the tongue over 5–10 minutes.

Bioavailability: About 30%, the same as combination tablets.

Strengths available: 2mg and 8mg tablets

Pros:

• Preferred during pregnancy and breastfeeding
• Fewer ingredients (no naloxone)
• May cause less irritation for sensitive individuals
• Works the same as combination products for most people

Cons:

• Slightly higher street value, so some providers hesitant to prescribe
• Not always covered by insurance without pregnancy documentation
• More expensive than generic combination products
• No abuse-deterrent naloxone component

Who it's best for: Pregnant or breastfeeding individuals, people who have documented reactions to naloxone (very rare), or those whose providers prefer mono-product for specific clinical reasons. Our breastfeeding guide covers safety during nursing.

Typical cost: $100–$200 per month, usually higher than generic combination products.

How to Choose the Right Formulation

With so many options, how do you decide? Here are the key factors to consider:

Your stage of treatment:

• Just starting? Sublingual films or tablets offer the most flexibility while you find your dose
• Interested in long-acting treatment? Ask whether a currently marketed injectable is clinically appropriate and covered
• Still adjusting? Stick with daily formulations for now

Your daily routine and preferences:

• Need structure? Daily sublingual formulations provide that
• Tired of daily medication? Monthly injections eliminate the routine
• Struggle with adherence? Long-acting options remove the decision

Insurance coverage:

• Generic sublingual products are often listed on formularies, but coverage varies
• Injectables may require prior authorization and are not covered by every plan
• Check your specific coverage through our insurance guides for Medicaid, Aetna, Blue Cross Blue Shield, and Cigna

Cost considerations:

• Generic sublingual is cheapest ($50–$150/month with insurance)
• Brand products and injectables cost more but may be covered
• Patient assistance programs exist for most formulations

Practical factors:

• Access to clinic for monthly injections?
• Dry mouth or oral issues that make sublingual difficult?
• Housing stability for storing daily medication?
• Privacy concerns about visible medication use?

Discuss all of these factors with your provider. The appropriate formulation depends on clinical history, current labeling, safety, availability, coverage, and preferences; no one product is automatically best for every new patient.

Switching Between Formulations

Many people change formulations as their recovery progresses. Common transitions include:

From sublingual to injection: Eligibility and transition instructions are product-specific. A clinician must confirm the current prescribing information and create the transition plan; do not time the change yourself.

From injection to sublingual: Extended-release medication can remain in the body for a prolonged period. Any transition back to a sublingual product must be planned and monitored by a clinician.

Between sublingual formulations: Products may differ in ingredients, absorption, strengths, and instructions. Use the new prescription and pharmacist counseling; do not assume the old dose or technique carries over unchanged.

Do not switch, overlap, stop, split, or retime buprenorphine formulations without the prescribing clinician's plan. Extended-release products can remain in the body for a prolonged period, which makes unsupervised transitions particularly risky.